Free flap transplantation transfers living tissue, together with its own blood supply, to repair severe soft-tissue defects or reconstruct limb and external-organ functions. Although advances in microsurgical anastomosis, instruments and robotic surgery have improved the quality of vascular connections, postoperative vascular crises remain a major perioperative complication. Such events can compromise flap viability, require emergency salvage surgery, prolong hospitalization and contribute to permanent impairment of limb function. The study was conducted at No. 971 Hospital of the People’s Liberation Army Navy in China using clinical records from January 2012 through August 2023. Among 1,084 records screened, investigators included 568 patients aged 6 years or older who completed free flap surgery. They excluded non-free flap procedures, operations converted to another procedure, patients younger than 6 and patients classified as American Society of Anesthesiologists Physical Status class IV or V.

To separate model development from later validation, the researchers divided the patients chronologically, using December 31, 2020 as the cutoff. Records from 402 earlier patients formed the training cohort, while 166 later patients formed the validation cohort. The training group included 42 vascular crises, or 10.4% of its patients, and the validation group included 21, or 12.7%. The overall median age was 44 years, with an interquartile range of 31–51 years, and the median operative duration was seven hours, with an interquartile range of 5.5–8.5 hours. Most participants were men. Common flap types included anterolateral thigh, forearm and thoracoumbilical flaps. Anterolateral thigh flaps had the greatest absolute number of crises and necroses, but the study did not establish flap type as an independent predictor or demonstrate that the observed counts represented higher within-type risks.

Vascular crisis was diagnosed through bedside assessment of flap color, temperature, capillary refill time, tension and bleeding after pinprick. A pale or gray flap with reduced temperature, prolonged or absent capillary refill and little or no bleeding was considered suspicious for arterial compromise. A dark-red or cyanotic flap with swelling, increased tension and profuse dark-red bleeding suggested venous compromise. Two senior microsurgeons independently assessed and confirmed all cases, resolving discrepancies through discussion or consultation with another senior microsurgeon. Of the 63 crises, 37 patients underwent surgical exploration; arterial crisis was confirmed in 22 and venous crisis in 15. Another 26 patients had findings consistent with mild venous crisis and improved with conservative measures, including removal of sutures to relieve tension, incision and bloodletting for decompression, and volume expansion. Seventeen flaps were lost overall, producing a flap survival rate of 97.0%.

Univariate screening in the training cohort identified 13 variables for inclusion in multivariable modeling. Stepwise multivariable logistic regression then identified four independent statistical associations with vascular crisis. Each 1 g/L increase in serum albumin was associated with an odds ratio of 0.927, with a 95% confidence interval of 0.868–0.991, indicating that higher albumin was associated with lower odds of crisis. Smoking had an odds ratio of 4.713 compared with non-smoking, with a 95% confidence interval of 2.184–10.171. Each 1 g/L increase in hemoglobin had an odds ratio of 0.971, with a 95% confidence interval of 0.952–0.990. Each additional unit of packed red blood cell transfusion had an odds ratio of 1.170, but its 95% confidence interval of 0.993–1.377 included 1 and its P value was 0.060. The authors nevertheless retained transfusion as one of the four variables in the nomogram. These retrospective associations do not show that changing any factor would prevent a crisis.

The nomogram translates the four inputs into points that are summed and converted into a predicted probability. The researchers also created a dynamic online calculator that returns a risk estimate and 95% confidence interval. In the training cohort, the area under the receiver operating characteristic curve was 0.817, with a 95% confidence interval of 0.747–0.887. In the later validation cohort, it was 0.852, with a 95% confidence interval of 0.774–0.929. Calibration analysis showed agreement between predicted and observed risk, with a mean absolute error of 0.019, corresponding to an average prediction error of 1.9%. Decision curve analysis indicated clinical utility across a modeled risk-threshold range of 1% to 51%. A complete-case sensitivity analysis produced results consistent with the primary analysis. The online tool and transparent point system make the model accessible without specialized computing equipment, but its usefulness still depends on accurate inputs and validation in the intended clinical setting.

Several biological pathways could connect the selected variables with flap failure, although the retrospective data cannot determine which mechanisms were responsible. The authors interpreted lower albumin as a marker of poorer perioperative nutritional or physiological condition, noting that low albumin can alter colloid osmotic pressure, promote edema and contribute to impaired microcirculation. Smoking was associated with the largest odds ratio in the model and has a plausible vascular relationship because tobacco constituents can affect endothelial function, vasoconstriction, inflammation and thrombosis. Hemoglobin was included because it determines oxygen-carrying capacity, although the relationship is complex: anemia may reduce oxygen delivery to a flap, while moderate to severe blood loss can trigger redistribution of blood flow away from peripheral tissues. The model measured these relationships statistically rather than testing them experimentally or establishing a causal pathway.

Packed red blood cell transfusion requires particular caution because the model cannot distinguish a direct transfusion effect from confounding by anemia, blood loss or hemodynamic instability. Transfusion may be administered after substantial blood loss or in response to high-risk anemia, so it can also act as an indicator of compromised circulatory status. The authors discussed possible effects of transfused blood, including reduced nitric oxide availability, enhanced endogenous coagulation and inflammatory and endothelial activation. Their mechanistic discussion also relied partly on previous animal research, which cannot establish clinical benefit or harm in patients. The retrospective association between transfusion and vascular crisis should therefore not be interpreted as evidence that transfusion causes the complication, nor does the model establish a safe or unsafe transfusion threshold for free flap surgery.

The model is notable for combining preoperative laboratory measures with smoking and a perioperative transfusion variable in a transparent logistic-regression framework, while its simplicity also defines its limitations. The retrospective, single-center design leaves room for selection, measurement and unmeasured-confounding biases. Seventy patients, or 12.3% of the cohort, had at least one missing value, principally unavailable preoperative liver or kidney test results and missing intraoperative urine-output data. The investigators imputed missing continuous values with means or medians according to distribution and categorical values with modes, then conducted a complete-case sensitivity analysis. The four-variable model did not explicitly include surgical site, flap type, number of anastomosed vessels or other measures of surgical quality. It also included only 63 endpoint events across the full dataset, so some coefficient estimates, particularly for transfusion, carry substantial uncertainty.

Validation was limited to a chronologically later subset from the same hospital rather than an independent external cohort. The validation sample was modest, containing only 21 vascular crises, and the confidence intervals around discrimination were correspondingly broad. Prospective, multicenter studies would be needed to determine whether the nomogram retains its performance across different institutions, flap procedures and patient populations, and whether using it to guide perioperative care improves outcomes. The findings do not show that the model can prevent thrombosis or reduce flap loss. Instead, they provide a calibrated risk estimate for postoperative vascular crisis based on four routinely available factors, offering a potential screening aid for closer observation while leaving real-world clinical value and generalizability for further study.

Subject of Research: Development and internal validation of a four-factor nomogram for predicting vascular crisis after free flap surgery.

Article Title: Construction and validation of a predictive nomogram for vascular crisis risk following free flap surgery

Article References: Qu, Y.-L., Xue, J., Du, X.-Y., Zhang, D.-D., Wang, Y., Zhu, Y.-L., & Wang, J.-F. (2026). Construction and validation of a predictive nomogram for vascular crisis risk following free flap surgery. Frontiers in Medicine, 13, Article 1930369. https://doi.org/10.3389/fmed.2026.1930369

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1930369

Keywords: free flap surgery, vascular crisis, risk prediction, clinical nomogram, flap thrombosis, serum albumin, smoking, hemoglobin, blood transfusion, internal validation, Construction, validation

The research, published in BMC Geriatrics by Mete Özer and colleagues at Başakşehir Çam and Sakura City Hospital, followed 72 patients aged 65 and older who underwent transtibial or transfemoral amputation for diabetic foot complications between January 2021 and June 2023 at a tertiary referral center. Vital status was tracked through July 31, 2025, giving the team a long observation window. The numbers they found are stark. Thirty-nine of the 72 patients, or 54.2 percent, died within 24 months of surgery. Kaplan–Meier analysis estimated 24-month survival at just 45.8 percent, with a 95 percent confidence interval of 34.1 to 56.8 percent. In other words, a patient entering the operating room for a major amputation in this cohort had roughly a coin flip’s chance of being alive two years later.

To find out what separated the survivors from those who died, the researchers turned to Cox proportional hazards regression, the standard statistical machinery for modeling time-to-event data. They tested a panel of preoperative laboratory parameters, all of which are drawn routinely before surgery. Three emerged as independent predictors of mortality. Higher hemoglobin was associated with increased risk, with an adjusted hazard ratio of 1.302 per unit increase (95 percent CI 1.041 to 1.628; p = 0.021). Lower platelet counts carried a slightly elevated hazard, with an adjusted hazard ratio of 0.9966 per platelet (95 percent CI 0.9939 to 0.9994; p = 0.017). Most striking was albumin, the liver-synthesized protein that serves as a classic marker of nutritional status and systemic inflammation: each unit decrease in albumin carried an adjusted hazard ratio of 0.868 (95 percent CI 0.813 to 0.927; p < 0.001), making it the strongest single laboratory signal in the model.

Some of these directions may seem counterintuitive at first glance. Higher hemoglobin, usually a sign of good oxygen-carrying capacity, predicted worse survival here. The authors’ framing suggests this likely reflects the physiology of chronic disease rather than a paradox: in patients with severe peripheral artery disease and chronic inflammation, elevated hemoglobin can accompany hemoconcentration, chronic hypoxia-driven erythropoiesis, and underlying cardiopulmonary strain. Low platelet counts, meanwhile, may reflect platelet consumption in the microvascular thrombosis that characterizes advanced diabetic vascular disease, or suppressed production in the context of systemic illness. Albumin’s role is the least surprising. Hypoalbuminemia is a well-established composite marker, integrating malnutrition, chronic inflammation, liver synthetic function, and capillary leak, all of which are common in geriatric patients whose diabetic foot disease has reached the point of amputation.

From these three biomarkers, the team built a simple 3-point score using receiver operating characteristic analysis and Youden-index-based thresholds, a method that picks the cutoff value maximizing the sum of sensitivity and specificity. One point was assigned for hemoglobin above 10.3 g/dL, one for a platelet count below 342.5 × 10⁹ per liter, and one for albumin below 28.5 g/L. The stratification that resulted was dramatic. Patients with a score of 2 or higher had an estimated 24-month survival of only 8.0 percent, compared with 66.0 percent among those scoring 0 or 1, a difference that was highly significant on log-rank testing (p < 0.001). The score achieved an area under the curve of 0.798 for predicting 24-month mortality, and the underlying Cox model earned an optimism-corrected concordance index of 0.712 after bootstrap correction, a technique that estimates how much the model’s apparent performance is inflated by being fit to the same data it is evaluated on.

Crucially, the researchers did not stop at building their own score; they benchmarked it against three established prognostic indices that clinicians already use in related contexts. The Prognostic Nutritional Index, which combines albumin and lymphocyte count, achieved an AUC of 0.735. The Geriatric Nutritional Risk Index, built from albumin and weight metrics, reached 0.739. The Hemoglobin–Albumin–Lymphocyte–Platelet score, a composite designed in oncology, managed only 0.590, barely better than chance. The new three-biomarker score showed numerically higher discrimination than all of them, suggesting that the specific combination and thresholds derived from this amputation population capture something the generic indices miss.

The clinical implications, if the findings hold up, are considerable. Major amputation decisions in frail older adults are among the most wrenching in surgery, balancing limb loss against the burden of a procedure that may offer limited life expectancy in return. A preoperative score computed from blood drawn for routine pre-anesthetic workup could help surgeons, anesthesiologists, and families have more honest conversations about goals of care, the intensity of perioperative support, and whether palliative pathways deserve equal consideration. It could also help stratify patients in future trials of post-amputation rehabilitation, wound care, and vascular interventions, where heterogeneous baseline risk often obscures treatment effects.

The authors are careful, appropriately so, about the limits of what they have built. The score is derived and evaluated in the same cohort of 72 patients, a single-center sample that cannot establish how the tool performs on unseen patients. Bootstrap optimism correction was applied only to the fixed three-biomarker Cox model, not to the full score derivation pipeline, so the reported AUC of 0.798 likely overstates true performance to some degree. Quantitative measures of ischemia severity were unavailable, and standardized assessments of neuropathy and frailty, both powerful predictors in geriatric surgical populations, were not incorporated. The researchers explicitly state that the score should be regarded as exploratory, that it should not replace comprehensive clinical and vascular assessment, and that external validation in independent cohorts is required before any clinical use.

Those caveats are worth emphasizing because the temptation to over-read a clean, memorable score is real. A 3-point tool built from three numbers is easy to remember and easy to compute at the bedside, and that simplicity is both its appeal and its danger. The thresholds, hemoglobin above 10.3 g/dL, platelets below 342.5 × 10⁹ per liter, albumin below 28.5 g/L, were tuned to this specific cohort, and cutoffs derived this way often shift when tested elsewhere. Still, the biological coherence of the three signals, spanning oxygen transport, thrombotic consumption, and nutritional reserve, gives the finding a plausibility that purely data-driven models often lack.

What the study ultimately offers is a hypothesis worth testing at scale: that the most common blood panel in the hospital already contains a meaningful forecast of survival after major amputation in older diabetic patients. With more than half of such patients dying within two years, and with existing nutritional and inflammatory indices performing only modestly, even a modest improvement in preoperative risk discrimination could change how these operations are planned and discussed. Until external validation arrives, the score belongs in the research column rather than the clinic, but it points toward a future where the decision to amputate is informed not only by what surgeons see in the wound, but by what the blood has been saying all along.

Subject of Research: Preoperative laboratory-based prediction of 24-month mortality after major lower extremity amputation in geriatric diabetic foot patients

Article Title: Development of an exploratory preoperative laboratory-based score for 24-month mortality after major lower extremity amputation in geriatric diabetic foot patients

Article References: Özer, M., İnce, Y., Korkmaz, T., Talmaç, M. A., & Özer, M. (2026). Development of an exploratory preoperative laboratory-based score for 24-month mortality after major lower extremity amputation in geriatric diabetic foot patients. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08468-6

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08468-6

Keywords: diabetic foot, major amputation, geriatrics, mortality prediction, prognostic score, albumin, hemoglobin, platelet count, Cox regression, nutritional index, external validation, peripheral artery disease

Kyrgyzstan, a predominantly mountainous country in Central Asia where approximately 94% of the territory lies at elevations ranging from 400 to over 7000 meters above sea level, has made remarkable progress in reducing childhood malnutrition over the past two decades. Between 1997 and 2014, the prevalence of stunting declined from 36.2% to 12.9%, according to UNICEF data. Despite this improvement, persistent regional disparities remain, particularly in high-altitude areas characterized by rural settlement patterns, limited infrastructure, and reduced access to healthcare services.

The research team, collaborating between Denmark and Kyrgyzstan, conducted an observational cross-sectional comparative study between February and June 2025. They recruited healthy schoolchildren aged 10 to 12 years from two settings: the rural villages of Ak-Muz and Ozgorush in the Naryn region, both located at 2400 meters above sea level, and School No. 96 in Bishkek, the capital, at approximately 800 meters. After screening 317 children and excluding 51, the final analysis included 266 participants: 123 from Bishkek and 143 from Naryn.

To participate, children had to have lived more than 50% of their lives in the study region, limiting migration noise in the samples. The team excluded children with chronic conditions such as asthma, diabetes, epilepsy, or thyroid disease, as well as those with acute infections or taking medications like corticosteroids or bronchodilators. Parents completed a 20-item questionnaire covering household demographics, early life factors, nutritional practices, healthcare access, socioeconomic indicators, and household smoking. The questionnaire allowed researchers to control for income category, maternal characteristics, dietary diversity, supplement count, vaccination status, and birthweight.

The measurements were comprehensive. Height was recorded to the nearest 0.5 centimeters using a stadiometer, weight to the nearest 0.05 kilograms, and waist and mid-upper arm circumferences with standard measuring tapes. Oxygen saturation and pulse rate were measured with a portable SpO2 monitoring system after 30 seconds of rest. Hand grip strength was assessed with an electronic hand dynamometer, with each child performing three maximum-effort attempts per hand. Lung function was measured using spirometry following American Thoracic Society and European Respiratory Society guidelines, with predicted values calculated against a Caucasian reference population from the Global Lung Function Initiative equations. Hemoglobin was measured from a pinprick of capillary blood using a Hemocue analyzer.

The results were striking. Children in Bishkek were significantly taller, averaging 146.4 centimeters compared to 143.7 centimeters in Naryn, and significantly heavier at 38.7 kilograms versus 36.0 kilograms. Height-for-age z-scores differed significantly, with Bishkek children at −0.1 and Naryn children at −0.6. However, BMI and BMI-for-age z-scores did not differ significantly between groups. Children in Naryn had significantly higher hemoglobin levels at 134.6 grams per liter compared to 120.2 grams per liter in Bishkek, significantly lower oxygen saturation at 95.5% versus 97.6%, and significantly stronger hand grip strength at 20.7 kilograms-force versus 19.4 kilograms-force.

Lung function findings were particularly intriguing. Unadjusted FEV1 and FVC values did not differ significantly between groups. But when expressed as percent predicted against a Caucasian reference population, Naryn children had significantly higher FEV1 percent predicted at 98.3% versus 93.7% and FVC percent predicted at 99.8% versus 94.6%. The FEV1/FVC ratio remained nonsignificant. Regression models controlling for height, weight, gender, and income category confirmed that Naryn children had approximately 7.7% larger FEV1 and 7.2% larger FVC than their Bishkek counterparts.

Height differences persisted even after controlling for covariates including demographics, income category, maternal factors, and birthweight. Notably, the researchers found a significant gender-altitude interaction: male children in Bishkek were significantly taller than their Naryn counterparts, adjusted for age, while female children from Bishkek were not significantly taller than their Naryn peers. The altitude effect on height was significant for males but not for females. This pattern was replicated in height-for-age z-score calculations. Birthweight was significantly lower among children born at higher altitude, consistent with documented associations between altitude exposure and reduced fetal growth, but birthweight only partially explained the observed height differences.

The researchers hypothesize that the lower stature and weight may be due to development at high altitude under hypobaric hypoxia rather than malnutrition alone. Previous authors have suggested that this may be due to an adaptive response in the fetus that maximizes oxygen delivery through a smaller placenta, and during child growth, the body directs available energy to critical oxygen-transporting organs rather than the musculoskeletal system. The superior lung function, stronger hand grip strength, and higher hemoglobin levels observed in Naryn children are adaptations associated with healthy development and high-altitude residence, not necessarily with malnourished populations. The respiratory findings appear less dependent on birthweight-related in-utero exposure and may instead reflect postnatal physiological adaptation to chronic hypoxia.

The study has limitations. The researchers acknowledge differential selection bias, as participants in the Naryn region were largely driven by healthcare scarcity, while citizens of the urban capital might have more confidence in their child’s healthy development. The study did not control for puberty status, which could explain the gender difference in height, as some children aged 10 to 12 were probably already in puberty. Kyrgyzstan struggles with air quality, particularly in Bishkek during winter months, and differences in chronic air pollution exposure between settings were not directly assessed. The researchers used a Caucasian reference population for lung function, as no reference exists for Kyrgyz children yet. The children in Naryn were examined during late winter while Bishkek children were examined during early summer, creating a stark environmental contrast.

Clinically, the findings are meaningful on a population basis. A difference of 2.7 centimeters in linear growth might not be clinically meaningful when observing individuals, but a difference of 0.5 standard deviations seen on a population basis is clinically meaningful. The 14 grams per liter difference in hemoglobin levels and the roughly 7% difference in FEV1 and FVC are clinically significant when assessing a patient, as it would be important to consider that these children develop in an environment with increased demand for nutrition and respiratory capacity. The 1.3-kilogram difference in hand grip strength corresponds to the average developmental increase seen over an entire year in Dutch reference populations.

The researchers emphasize that their findings highlight the need to interpret WHO growth standards with caution when considering high-altitude pediatric populations. While the developmental profile may be supported by adaptation and acclimatization rather than malnutrition, the findings are observational and do not call for less investment in pediatric healthcare. If anything, attention to childcare and development should remain a continued focus, precisely because the development of these children is influenced by multiple factors and is hard to interpret by traditional standards such as linear growth alone. Future research employing longitudinal designs tracking children into adolescence and adulthood would help determine whether the observed gender differences in height persist and whether highland children’s functional advantages translate into long-term health benefits or limitations.

Subject of Research: Altitude and child development in Kyrgyzstan

Article Title: Altitude and child development: A cross‐sectional comparative study of children in urbanized low‐altitude and rural high‐altitude settings in Kyrgyzstan

Article References: Olsen, A. B. T., Isaeva, E., Umetalieva, M., Osmonbaeva, N., Wright, S. V., Serefoglu, L. D. L., Kretzchmar, F. N., Høegh, T. D., Kjærgaard, J., Nielsen, K. G., Sooronbaev, T., & Poulsen, A. (2026). Altitude and child development: A cross‐sectional comparative study of children in urbanized low‐altitude and rural high‐altitude settings in Kyrgyzstan. Physiological Reports, 14(19), Article e71132. https://doi.org/10.14814/phy2.71132

Image Credits: AI Generated

DOI: 10.14814/phy2.71132

Keywords: child development, high altitude, Kyrgyzstan, hypobaric hypoxia, lung function, hemoglobin, stunting, pediatric physiology, Altitude, child, development, cross

The study, published in Frontiers in Chemistry, harnessed ESM3, a generative protein language model from EvolutionaryScale that processes sequences, structures, and functions together. The same model family made headlines when it generated a fluorescent protein so distant from known relatives that it appeared to mimic five hundred million years of evolution. Most AI design pipelines, however, deliberately avoid touching ligand-binding sites, because a single careless mutation can wreck the delicate electrostatics that hold a cofactor in place. They also rarely benchmark their predictions against well-characterized natural mutations. The new work confronts both limitations head-on, using a clinically documented variant as its yardstick.

That yardstick is hemoglobin Fort de France, a naturally occurring human variant first described in 1977, in which histidine 45 in the alpha chain is replaced by arginine. The mutation is known to raise oxygen affinity while preserving structural integrity, a phenotype later confirmed by nuclear magnetic resonance studies. Before generating any models, the researchers mapped the heme-binding pocket and found that histidine 87, the proximal histidine that directly coordinates the heme iron, is untouchable, whereas position 45 is suitable for modification. Crucially, the homologous position in myoglobin, the oxygen-storage protein of muscle, is naturally occupied by arginine, which forms a robust salt bridge with the heme 6-propionate group, stronger than the polar contact mediated by histidine in hemoglobin.

When ESM3 was asked to score the evolutionary fitness of all nineteen possible substitutions at position 45, the wild-type histidine scored zero by definition, while arginine received one of the highest positive scores, 2.6, indicating a change highly compatible with structure and function. The model then generated the engineered variant, dubbed esmHb, using a structure-focused prompting strategy. The team systematically tested how much of the wild-type template structure had to be retained for accurate generation, discovering a nonlinear relationship between retained structural tokens and sequence fidelity, with a retention threshold of roughly 47 contiguous N-terminal tokens needed to halve the local deviation at the mutation site. The optimized protocol achieved something remarkable: a variant carrying exactly one mutation, with one hundred percent sequence identity to the wild-type alpha chain everywhere else, and a local root-mean-square deviation of about one to one and a half angstroms around the engineered residue.

Validation then proceeded through a battery of biophysical simulations. FoldX calculations of folding free energy yielded minus 12.22 kilocalories per mole for the wild-type dimer but minus 18.48 for esmHb, a substantially more favorable value indicating enhanced thermodynamic stability. Monte Carlo refinement with the Rosetta protocol, which explored one thousand trajectories and selected the lowest-energy structures under the Metropolis criterion, consistently assigned lower energy scores to the engineered variant. Molecular docking with AutoDock4 placed the heme-binding affinity of esmHb at minus 11.79 kilocalories per mole, improved over the wild-type value of minus 8.42 and approaching the minus 12.4 of myoglobin itself, the protein whose heme pocket the design was inspired by.

Triplicate molecular dynamics simulations in AMBER, each running five hundred nanoseconds in explicit water at physiological temperature, painted a consistent dynamic picture. The engineered protein relaxed to marginally lower backbone deviations, about half an angstrom, suggesting greater rigidity, while fluctuations in the heme-binding pocket dropped from 4.11 to 3.33 angstroms around position 45. The radius of gyration showed esmHb maintaining a slightly more compact conformation, roughly 19.0 versus 19.5 angstroms, and the heme ligand itself deviated less in the mutant complex. Free energy landscapes derived from principal component analysis revealed perhaps the most striking difference: esmHb samples a single, well-defined energy basin, whereas the wild-type protein wanders across a broader landscape with multiple shallow minima, implying reduced conformational entropy and enhanced kinetic stability for the engineered fold.

Binding free energy calculations from the trajectories reinforced the trend. Using the MM-GBSA and MM-PBSA implicit solvation methods, the researchers found more favorable protein-heme interactions for esmHb, with MM-PBSA reaching statistical significance at p equals 0.03, and stronger protein-protein interactions significant under both methods at p equals 0.04. The authors are careful to interpret the MM-GBSA results as a suggestive trend rather than definitive evidence, a caution that reflects the inherent uncertainty of these estimators. Quantum mechanical calculations added a final layer: density functional theory at the long-range corrected omegaB97XD level, applied to truncated heme-site models extracted from the equilibrated trajectories, showed the formal oxygenation reaction of esmHb to be thermodynamically more favorable by 23.2 kilocalories per mole, with reaction energies of minus 173.1 versus minus 149.9 kilocalories per mole.

The mechanistic story ties the numbers together. The arginine at position 45 forms a salt bridge with the heme 6-propionate, anchoring the cofactor and modulating geminate recombination and oxygen affinity in proportion to its basicity, a dynamic molecular doorstop mechanism first illuminated in myoglobin studies. The computational findings align with experimental data on the natural Fort de France variant, whose increased oxygen affinity and confirmed structural integrity corroborate the DFT results. In effect, ESM3 rediscovered and rationalized a beneficial mutation that nature and clinical hematology had already validated, bridging statistical prediction with empirical observation.

The framework extends well beyond hemoglobin. The authors argue that integrating protein language models with molecular dynamics, docking, and quantum chemistry establishes a generalizable pipeline for engineering therapeutic proteins, applicable to hemoglobinopathies, artificial blood substitutes, enzyme design, and sustainable biomaterials. The limitations are acknowledged with equal candor: ESM3 may inherit biases toward well-represented protein families, its statistical patterns cannot capture subtle quantum effects, and the His45Arg substitution was inspired by myoglobin homology rather than purely de novo generation, highlighting the model’s caution around high-risk changes. Experimental benchmarking of oxygen-binding kinetics and in vivo stability remains essential before any therapeutic claim, since computational metrics do not fully replicate physiological complexities such as allosteric effectors. Still, as a proof of concept, the work marks a milestone in AI-driven protein engineering, demonstrating that a language model trained on evolutionary statistics can safely redesign one of biology’s most critical molecules, one residue at a time.

Subject of Research: Computational protein engineering of hemoglobin using a protein language model

Article Title: Engineering a hemoglobin variant with enhanced stability and oxygen affinity using a protein language model

Article References: Shityakov, S., Novikov, A. S., Skorb, E. V., & Dandekar, T. (2026). Engineering a hemoglobin variant with enhanced stability and oxygen affinity using a protein language model. Frontiers in Chemistry, 14, Article 1898272. https://doi.org/10.3389/fchem.2026.1898272

Image Credits: AI Generated

DOI: 10.3389/fchem.2026.1898272

Keywords: protein language model, ESM3, hemoglobin, protein engineering, molecular dynamics, oxygen affinity, artificial blood substitutes, computational chemistry, Engineering, variant, enhanced, stability

Yingyangbao, whose name translates roughly as nutrition package, is a specially formulated micronutrient supplement designed to be mixed into a child’s regular complementary foods. It contains a dense blend of proteins, vitamins, and minerals, including iron, which is critical for preventing the anemia that so often shadows the weaning period in resource-limited settings. The supplement was developed as a practical response to a persistent problem: between roughly six months and two years of age, children’s rapid growth outstrips the iron and other nutrients available from breast milk alone and from the often monotonous plant-based gruels that dominate complementary feeding in many rural households. Without intervention, this gap frequently manifests as iron-deficiency anemia, which in early childhood is associated with impaired cognitive development, weakened immunity, and long-term developmental deficits.

The scale of the new analysis is one of its greatest strengths. Across eight annual survey rounds conducted from 2016 through 2023, the researchers enrolled a total of 16,895 children aged 6 to 23 months. Rather than relying on convenience samples, the team employed a rigorous multi-stage sampling design that combined probability proportionate to size sampling with random equidistant selection, drawing participants from seven counties in Hunan Province that participate in the national NIPCPA program. This methodology ensures that the children surveyed are statistically representative of the broader population of infants and toddlers in these impoverished areas, lending considerable weight to the temporal trends the study documents.

The anthropometric and hematological picture that emerged from the eight waves of data collection is broadly encouraging. On average across the study period, the children measured 76.8 centimeters in body length, weighed 9.95 kilograms, and carried a mean hemoglobin concentration of 118.8 grams per liter. The average prevalences of the three classic markers of undernutrition were low: stunting, a measure of chronic malnutrition reflected in height-for-age, affected 4.4 percent of children; underweight, which combines weight and height deficits, affected 3.2 percent; and wasting, the acute thinness that signals recent severe deprivation, affected 3.0 percent. By World Health Organization benchmarks, these figures place the studied population in a comparatively favorable position, a notable achievement for regions historically among the most nutritionally vulnerable in China.

The year-by-year trajectories tell an even more compelling story. Stunting prevalence declined by 30.9 percent over the study window, falling from 5.5 percent in 2016 to 3.8 percent in 2023. Underweight fell even more dramatically, dropping 58.0 percent from 5.0 percent to 2.1 percent. Wasting decreased from 3.8 percent in 2016 to 1.5 percent in 2023, though the researchers note it peaked at 3.8 percent in both 2016 and 2022, hinting at possible disruptions, perhaps related to the COVID-19 pandemic, that briefly reversed gains before the downward trend resumed. But the most dramatic transformation was in anemia. Overall anemia prevalence collapsed from 29.3 percent in 2016 to 6.2 percent in 2023, a 78.8 percent relative decline that moved the problem from a moderate public health concern to what the authors characterize as a mild one.

To determine whether Yingyangbao consumption itself was driving these improvements, the researchers fitted multivariate unconditional logistic regression models that adjusted for potential confounding factors. The analysis revealed a clear and dose-responsive relationship between the supplement and children’s anemia status, though interestingly, no significant association emerged between Yingyangbao consumption and stunting, underweight, or wasting. This pattern makes physiological sense: the supplement’s iron content directly targets the hematological pathway, while linear growth and body composition depend on a broader array of dietary, genetic, infectious, and socioeconomic influences that a single micronutrient sachet cannot fully address.

The quantitative findings on anemia are striking in their precision. Compared with children who did not consume Yingyangbao at all, those classified as effective consumers were substantially less likely to be anemic. The adjusted odds ratios were 0.43 for mild anemia, 0.20 for moderate anemia, and 0.38 for overall anemia, meaning effective consumption was associated with roughly an 80 percent reduction in the odds of moderate anemia. Even children classified as non-effective consumers, meaning those who received the supplement but did not consume it at the recommended frequency or consistency, fared better than non-consumers, with adjusted odds ratios of 0.61 for mild anemia, 0.41 for moderate anemia, and 0.57 for overall anemia. The distinction between effective and non-effective consumption underscores a practical lesson for program implementers: distribution alone is not enough, and caregiver education about proper daily use matters.

Duration of consumption added a further dimension to the dose-response relationship. Children who consumed Yingyangbao for fewer than six months had adjusted odds ratios of 0.52 for mild anemia, 0.29 for moderate anemia, and 0.54 for overall anemia compared with non-consumers. Those with six to eleven months of consumption showed slightly stronger protection, with corresponding odds ratios of 0.50, 0.24, and 0.42. The longest exposure category, twelve months or more, yielded the best outcomes for moderate anemia, with an odds ratio of 0.21, and an odds ratio of 0.35 for overall anemia. The gradient across duration categories suggests that sustained, habitual use of the supplement allows iron stores to accumulate and hematological status to stabilize, reinforcing the case for continuous rather than intermittent supplementation during the vulnerable 6-to-23-month window.

From a public health policy standpoint, the study offers a rare longitudinal validation of one of the world’s largest targeted nutrition interventions. The NIPCPA program, which distributes Yingyangbao free of charge to families in designated poor counties, has often been evaluated in short-term trials, but evidence spanning eight consecutive years of real-world implementation is comparatively scarce. The Hunan data suggest that the program has not only maintained consistent delivery across nearly a decade but has also contributed to a population-level shift in child hematological health. The authors conclude that while stunting, underweight, and wasting in these poor areas of Hunan are now at low levels, anemia remains a mild public health problem, and Yingyangbao intervention can effectively improve children’s anemia status, with better results from effective consumption and longer duration of use.

There are, of course, caveats inherent in the study design. As a series of cross-sectional surveys rather than a randomized controlled trial, the analysis can demonstrate strong associations but cannot definitively prove causation, and other concurrent improvements in rural living standards, healthcare access, and dietary diversity during this period may have contributed to the observed declines. Nevertheless, the consistency of the dose-response patterns, the large sample size, the representative sampling frame, and the adjustment for confounders all strengthen the plausibility that Yingyangbao played a meaningful role. For global health practitioners searching for scalable, low-cost models to combat early childhood anemia, the Hunan experience offers a compelling template: a simple fortified sachet, delivered reliably and consumed consistently, can help turn one of the most stubborn markers of early-life deprivation into a rapidly receding problem.

Subject of Research: Yingyangbao supplementation and child undernutrition and anemia trends in poor areas of Hunan, China

Article Title: Temporal trends (2016–2023) of undernutrition and anemia among children in poor areas, and relationship between Yingyangbao intervention and children’s nutrition status: a multiwave cross-sectional study in Hunan, China

Article References: Li, H., Liao, M., Xiao, J., Huang, Q., Feng, B., Tu, Y., Huang, G., & Zheng, J. (2026). Temporal trends (2016–2023) of undernutrition and anemia among children in poor areas, and relationship between Yingyangbao intervention and children’s nutrition status: a multiwave cross-sectional study in Hunan, China. BMC Public Health. https://doi.org/10.1186/s12889-026-29922-5

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29922-5

Keywords: Yingyangbao, child nutrition, anemia, undernutrition, stunting, wasting, underweight, hemoglobin, micronutrient supplementation, public health, China, NIPCPA

The study, led by Xing Wang and colleagues at West China Hospital of Sichuan University, systematically searched PubMed, Embase, MEDLINE, and the Cochrane Library for randomized controlled trials comparing red blood cell transfusion thresholds in patients with acute brain injury, a category encompassing traumatic brain injury, aneurysmal subarachnoid hemorrhage, and spontaneous intracerebral hemorrhage. The final analysis pooled six randomized controlled trials comprising 2,599 patients, evaluating four distinct hemoglobin thresholds of 7, 8, 9, and 10 grams per deciliter. Rather than simply splitting trials into liberal versus restrictive camps, the researchers used Bayesian network meta-analysis, a statistical framework that combines direct comparisons within trials with indirect comparisons across the network of treatments, allowing all four thresholds to be ranked against one another even where head-to-head data were sparse.

The headline result concerns functional outcome, the measure that matters most to patients and families after brain injury. Compared with a transfusion threshold of 7 grams per deciliter, the most restrictive strategy evaluated, a threshold of 9 grams per deciliter was associated with a lower risk of unfavorable functional outcome, with a risk ratio of 0.86 and a 95 percent credible interval of 0.78 to 0.94. Crucially, this estimate rested on direct evidence from two randomized trials, lending it considerable weight. When compared against a threshold of 8 grams per deciliter, the estimate again favored the 9 gram trigger, with a risk ratio of 0.79, but the credible interval of 0.63 to 1.00 just touched the boundary of statistical significance, and this comparison relied on indirect evidence chains rather than direct head-to-head trials.

On the question of mortality, the picture was more equivocal. No threshold demonstrated a clear survival advantage over the others, and the analysis found no significant differences in adverse events, including infectious complications and thromboembolic events, across the evaluated strategies. This safety profile matters, because one of the principal theoretical objections to liberal transfusion in the critically ill has been the fear that additional transfusions would drive infections, venous thrombosis, or transfusion-related circulatory overload. In this analysis, the 9 gram per deciliter threshold achieved its functional benefit without a measurable penalty in these safety domains.

To quantify the relative standing of each strategy, the researchers employed the surface under the cumulative ranking curve, or SUCRA, a metric that converts the network of comparisons into a single probability-based ranking for each treatment. The 9 gram per deciliter threshold ranked highest on SUCRA values for both mortality and neurological outcomes, emerging as the most favorable option among those evaluated. The 7 gram per deciliter threshold, long the default restrictive trigger in general intensive care based on landmark trials in non-neurological patients, fared comparatively poorly for neurological recovery, even though it remains widely endorsed for other critically ill populations.

The biological rationale for a higher trigger in brain injury is grounded in cerebral physiology. The injured brain is exquisitely vulnerable to secondary insults, and anemia reduces arterial oxygen content at precisely the moment when damaged tissue may be operating near the threshold of hypoxic injury. In regions of compromised autoregulation, the normal compensatory response of increasing cerebral blood flow may be blunted, meaning that a falling hemoglobin concentration translates more directly into tissue hypoxia. Experimental and observational work has linked anemia after traumatic brain injury and subarachnoid hemorrhage to worse neurological outcomes, and cohort studies such as CENTER-TBI and the SYNAPSE-ICU study have documented how frequently anemia occurs and how variable transfusion practice remains across intensive care units worldwide.

The authors also probed the sources of inconsistency among prior studies through meta-regression, a technique that examines whether trial-level characteristics modify treatment effects. Their analysis suggested that the baseline hemoglobin level of enrolled patients may represent a potential source of heterogeneity in how liberal transfusion strategies influence functional outcomes. In practical terms, patients who arrive anemic may respond differently to a higher transfusion trigger than those who only drift downward gradually, a finding that could help explain why earlier syntheses of liberal versus restrictive strategies produced conflicting conclusions.

The new analysis arrives amid a burst of high-profile trials that have reshaped, but not settled, this debate. The 2024 HEME trial published in the New England Journal of Medicine found no clear mortality or functional difference between liberal and restrictive strategies in traumatic brain injury, while a subsequent 2025 trial in aneurysmal subarachnoid hemorrhage likewise reported nuanced results. Multiple systematic reviews and meta-analyses published between 2024 and 2026 have wrestled with these data, some favoring liberal approaches for neurological recovery and others finding no effect. What distinguishes the current work is its network design: instead of forcing every trial into a binary liberal-versus-restrictive comparison, it treats each numeric threshold as a distinct treatment and ranks them simultaneously, a method aligned with PRISMA extension reporting standards for network meta-analyses and with GRADE and Cochrane risk-of-bias frameworks for evidence appraisal.

Nevertheless, the authors and the broader neurocritical care community caution against premature certainty. Six trials and 2,599 patients represent a modest evidence base for a question of this magnitude, and the thresholds themselves were operationalized differently across trials. The finding that the 9 versus 8 gram comparison lacked statistical significance underscores the limits of indirect estimation, and SUCRA rankings, while useful for decision-making, inherit every uncertainty present in the underlying network. Guidelines from the American Heart Association and American Stroke Association and neurocritical care societies have so far stopped short of mandating a single trigger, and the new analysis is unlikely to change that stance on its own.

Even so, the study represents a meaningful step toward precision in one of neurocritical care’s most persistent controversies. If the 9 gram per deciliter threshold is confirmed in adequately powered, dedicated trials that directly compare intermediate triggers, hundreds of thousands of patients with traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage could see transfusion decisions guided by evidence rather than by institutional habit. For now, the message for clinicians is nuanced but actionable: in the injured brain, the general intensive care rule of waiting until hemoglobin falls to 7 grams per deciliter may be too conservative, and the intermediate territory around 9 grams per deciliter deserves careful consideration when the goal is protecting neurological recovery rather than merely keeping patients alive.

Subject of Research: Optimal red blood cell transfusion thresholds for patients with acute brain injury

Article Title: Optimal Transfusion Thresholds in Patients with Acute Brain Injury: A Bayesian Network Meta-analysis of Randomized Controlled Trials

Article References: Wang, X., Fu, W., Chen, W., Ma, L., & You, C. (2026). Optimal Transfusion Thresholds in Patients with Acute Brain Injury: A Bayesian Network Meta-analysis of Randomized Controlled Trials. Neurocritical Care. https://doi.org/10.1007/s12028-026-02674-1

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02674-1

Keywords: transfusion thresholds, acute brain injury, hemoglobin, anemia, Bayesian network meta-analysis, randomized controlled trials, traumatic brain injury, subarachnoid hemorrhage, neurocritical care, functional outcome, mortality, intensive care

Anemia, defined as a hemoglobin concentration below a given threshold, remains one of the most common nutritional problems on the planet, and pregnant women and adolescent girls bear a disproportionate share of the burden. The condition is far from benign. Iron deficiency, the leading cause of anemia, impairs oxygen delivery to tissues, including the brain, and has long been suspected of influencing mood, cognition, and energy levels. At the same time, perinatal depression affects a substantial proportion of women worldwide, with prevalence estimates particularly high in low- and middle-income countries, and it carries consequences that ripple outward to infant development, mother-child bonding, and even birth outcomes such as preterm delivery and low birth weight. Whether the two conditions are causally connected, however, has been surprisingly difficult to pin down.

To address that uncertainty, the research team conducted a systematic review and dose-response meta-analysis, searching eight bibliographic databases for peer-reviewed studies published from 1980 onward that reported on the relationship between maternal hemoglobin status or anemia and maternal depression during pregnancy or up to one year postpartum. The screening process began with 718 titles and abstracts, from which 42 studies ultimately met the eligibility criteria for inclusion. Rather than pooling results with conventional fixed or random-effects techniques alone, the investigators used a flexible Bayesian meta-regression approach, a statistical framework capable of modeling nonlinear relationships between hemoglobin concentration and depression risk while accommodating the considerable variation in study designs, populations, and measurement methods.

The dose-response curves generated by the models are the study’s most technically interesting output. In longitudinal studies, the analysis of peripartum depression drew on 21 observations from 10 studies, while the postnatal depression analysis used 19 observations from 9 studies. Across these curves, the risk of depressive symptoms was minimized at a mean hemoglobin concentration of approximately 128 grams per liter and rose steadily as concentrations dropped. This pattern is biologically plausible. Hemoglobin is the body’s principal oxygen carrier, and the neural circuits that regulate mood are metabolically demanding. Iron, which sits at the center of every hemoglobin molecule, also serves as a cofactor in the synthesis of dopamine and serotonin, neurotransmitters intimately involved in mood regulation. Prior research, including work by Corwin and colleagues showing that low hemoglobin is a risk factor for postpartum depression, and studies linking plasma ferritin measured shortly after delivery to depressive symptoms, has hinted at these mechanisms.

Pregnancy complicates the picture in an important way. During gestation, plasma volume expands substantially, diluting red blood cells and producing a physiological hemodilution that lowers hemoglobin concentrations even in iron-replete women. One recent large-scale cohort study even proposed gestational hemodilution itself as a putative risk factor for postpartum depression. This means that interpreting a low hemoglobin reading during pregnancy requires care: it may reflect normal dilution, true iron deficiency, or both. The World Health Organization has recently updated its guidance on hemoglobin cutoffs for defining anemia, including adjustments for elevation and other factors, and the new analysis aligns itself with this evolving landscape, underscoring how definitional choices can shift estimates of global anemia burden and, by extension, the size of the population potentially at risk.

Yet the authors are emphatic that their headline finding comes with a major caveat. Under the Burden of Proof framework, which assigns a star rating from one to five to reflect the strength of evidence for a risk-outcome relationship, the hemoglobin-depression link received only one star out of five. That rating stems from substantial between-study heterogeneity: the included studies varied widely in how they measured hemoglobin, when during pregnancy or the postpartum period they measured it, how they defined and assessed depression, and which confounding factors they controlled for. Many relied on screening instruments such as the Edinburgh Postnatal Depression Scale rather than clinical diagnosis, and few accounted for the full range of socioeconomic, obstetric, and psychological factors that influence both anemia and mood. The one-star rating does not mean the association is absent; it means the evidence base is too weak to support strong causal claims.

This is precisely what the Burden of Proof framework, first described by Zheng and colleagues in Nature Medicine in 2022, was designed to expose. Traditional meta-analyses often report a pooled effect size without systematically grading how much confidence readers should place in it. The framework borrows ideas from GRADE methodology but pushes further, applying conservative risk-function modeling that penalizes sparse, heterogeneous, or biased data. The result is a more honest accounting: a risk curve can be estimated, but its evidentiary weight is made explicit. For low hemoglobin and peripartum depression, the message is that a plausible and potentially modifiable risk factor has been identified, but the field needs far better studies before iron supplementation or transfusion policies can be justified on mental health grounds alone.

The practical implications are nonetheless significant. Anemia during pregnancy is already a target of global health policy, with routine iron and folic acid supplementation recommended in antenatal care guidelines. If future research confirms that correcting low hemoglobin also reduces the risk of perinatal depression, the case for aggressive screening and treatment would strengthen considerably, particularly in settings where both anemia and perinatal mental disorders are highly prevalent. Maternal depression is associated with impaired early interactions, compromised parenting and safety practices, and adverse effects on child cognitive and emotional development, so even a modest causal contribution from anemia would translate into a meaningful population-level burden. Conversely, if the association turns out to be largely confounded, by poverty, chronic stress, or poor overall nutrition, interventions targeting hemoglobin alone would miss the mark.

The research team, which includes investigators from the Institute for Health Metrics and Evaluation, the University of Queensland, and the Queensland Centre for Mental Health Research, and which received support from the Gates Foundation, is explicit about what comes next. High-quality longitudinal studies with robust, repeated measurement of hemoglobin and validated assessment of peripartum depression are needed to strengthen the evidence base. Such studies should ideally track iron status across trimesters, distinguish iron deficiency from other causes of low hemoglobin, and use diagnostic interviews rather than screening questionnaires alone. In the meantime, the study offers clinicians and policymakers a carefully quantified signal: the lowest observed risk of peripartum depression occurs near a hemoglobin concentration of 128 grams per liter, and the evidence linking lower levels to higher risk, while weak by the strictest standards, is consistent enough to warrant attention. For a condition as common as anemia and an outcome as consequential as maternal depression, that combination of plausibility and uncertainty is exactly the kind of finding that should galvanize the next generation of research.

Subject of Research: The association between low maternal hemoglobin concentration and peripartum depressive symptoms assessed through a systematic review and Burden of Proof meta-analysis

Article Title: The effect of low hemoglobin on maternal peripartum depressive symptoms: a Burden of Proof framework

Article References: Perumal, N., McHugh, T. A., Rhee, D. K., Teply, C., Taylor, H., Tandiono, H., Okorie, I., Nanditha, N. G. A., Noyes, T. S., Chung, E., Santomauro, D., Ferrari, A., Dirac, M. A., McLaughlin, S. A., Gilbertson, N. M., Murray, C. J. L., Hay, S. I., & Kassebaum, N. J. (2026). The effect of low hemoglobin on maternal peripartum depressive symptoms: a Burden of Proof study. Nature Mental Health. https://doi.org/10.1038/s44220-026-00716-3

Image Credits: AI Generated

DOI: 10.1038/s44220-026-00716-3

Keywords: anemia, hemoglobin, peripartum depression, postpartum depression, pregnancy, Burden of Proof, meta-analysis, iron deficiency, maternal mental health, Bayesian meta-regression, global health, risk factors

The research team, led by Yiqing Hu and Zhigang Chen, analyzed data from 340 patients with advanced non-small cell lung cancer who were treated with immune checkpoint inhibitors in real-world clinical settings. Rather than chasing expensive molecular signatures, the investigators turned to hemoglobin, the oxygen-carrying protein in red blood cells, and to the albumin-to-alkaline phosphatase ratio, a calculation that weighs a marker of nutritional status and liver function against an enzyme often elevated by tumor activity in bone and tissue. Both measurements, the team found through Cox regression analysis, stood out as independent predictors of how long patients remained free of cancer progression.

The logic behind these two biomarkers is rooted in the biology of the tumor microenvironment. Anemia in cancer is not merely a symptom of fatigue; recent work has shown that tumors can actively hijack macrophages to secure iron supplies, promoting both metastasis and anemia, and that tumor-induced alterations in erythroid precursor cells can suppress the immune response and blunt the effectiveness of anti-PD-1 and anti-PD-L1 therapies. Low hemoglobin, in other words, may be a visible fingerprint of an immunosuppressive state that undermines the very drugs designed to unleash the immune system.

The albumin-to-alkaline phosphatase ratio tells a complementary story. Albumin reflects the body’s nutritional reserve and synthetic liver capacity, while alkaline phosphatase rises when cancer spreads to bone or when inflammation churns through the biliary system. A low ratio therefore signals a patient whose nutritional reserves are depleted while tumor burden and inflammatory activity are high. Previous meta-analytic work has already linked pretreatment albumin-to-alkaline phosphatase ratios to outcomes in lung cancer, but the Suzhou team went a step further by fusing the two measures into a single, easy-to-compute score.

They named it the Nutritional Inflammatory Hematological Risk Index, or NIHRI. The construction is deliberately simple: hemoglobin is dichotomized at 120 grams per liter, the standard clinical threshold for anemia, and the albumin-to-alkaline phosphatase ratio is dichotomized at 0.56, a cutoff derived from the analysis. Each adverse value earns one point, so every patient lands in one of three groups: low risk with zero points, intermediate risk with one point, or high risk with two points. When the researchers stratified their 340 patients this way, the differences in progression-free survival between the groups were highly statistically significant, with a p-value below 0.001.

What makes the finding clinically meaningful is not just the stratification but the way it performs alongside established prognostic factors. The team built a nomogram, a graphical scoring tool that clinicians can use at the bedside, incorporating the NIHRI together with tumor stage, PD-L1 expression status, and the Eastern Cooperative Oncology Group performance status, the standard measure of a patient’s functional fitness. The combined model achieved a concordance index of 0.70, rising to an optimism-corrected 0.69 after bootstrapping, an internal validation technique that guards against statistical overfitting by repeatedly resampling the data.

The predictive accuracy of the nomogram grew stronger the longer the time horizon. The area under the receiver operating characteristic curve, a standard measure of discrimination, reached 0.81 for one-year progression-free survival, 0.85 for two-year survival, and 0.88 for three-year survival. Decision curve analysis, a method that quantifies the net clinical benefit of using a model to guide treatment choices rather than treating everyone identically, confirmed that the tool offered acceptable clinical utility across a meaningful range of threshold probabilities. In practical terms, the model is accurate enough to be worth acting on.

The implications reach into one of the most consequential decisions in modern oncology: who should receive immunotherapy, in what combination, and with what intensity of monitoring. Patients flagged as high risk by the NIHRI might be candidates for closer surveillance, earlier imaging, combination regimens that pair checkpoint inhibitors with chemotherapy or anti-angiogenic agents, or enrollment in trials of strategies designed to overcome resistance. Conversely, patients in the low-risk tier might be spared the added toxicity of aggressive combination therapy if single-agent immunotherapy is likely to suffice. Because the index requires nothing beyond a complete blood count and a standard chemistry panel, it can be applied at essentially any oncology clinic in the world without new infrastructure or cost.

The study’s real-world design is both its strength and its caveat. Randomized trials enroll carefully selected patients, but this cohort reflects the heterogeneity of everyday clinical practice, where age, comorbidities, and performance status vary widely. That breadth suggests the index could generalize well, though the authors themselves note the retrospective nature of the analysis and the need for external validation in independent, ideally prospective, cohorts before the tool enters routine use. The work was supported by the State Key Laboratory of Radiation Medicine and Protection at Soochow University, and the authors declare no competing interests.

Still, the broader message resonates far beyond lung cancer. As immunotherapy costs strain health systems worldwide and biomarker-guided medicine grows ever more complex, the idea that two numbers from a routine blood draw can meaningfully forecast who will benefit from a hundred-thousand-dollar therapy is a reminder that the body’s basic physiology, nutrition, inflammation, and oxygen transport, remains deeply intertwined with the immune system’s war on cancer. The NIHRI will not replace molecular profiling or PD-L1 testing, but as a cheap, non-invasive first filter it may help clinicians personalize one of oncology’s most important decisions, and it may inspire similar indices across other tumor types where immunotherapy outcomes remain stubbornly unpredictable.

Subject of Research: A prognostic blood-based index combining hemoglobin and albumin-to-alkaline phosphatase ratio for predicting outcomes in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitor therapy.

Article Title: Nutritional inflammatory hematological risk index predicts clinical outcomes in patients with advanced NSCLC receiving immunotherapy

Article References: Hu, Y., Chen, Z., Yao, M., & Gan, L. (2026). Nutritional inflammatory hematological risk index predicts clinical outcomes in patients with advanced NSCLC receiving immunotherapy. Medical Oncology, 43(11), Article 329. https://doi.org/10.1007/s12032-026-03440-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03440-1

Keywords: non-small cell lung cancer, immune checkpoint inhibitors, NIHRI, hemoglobin, albumin-to-alkaline phosphatase ratio, nomogram, progression-free survival, PD-L1, prognostic biomarkers, anemia, immunotherapy, ECOG performance status

α-thalassemia arises when the α-globin genes, which encode one of the two protein chains of adult hemoglobin, are deleted or defective. Healthy people carry four copies of the α-globin gene, two on each chromosome 16. Carriers with three or two functional copies are usually asymptomatic, and the carrier alleles are extraordinarily common in malaria-endemic regions, reaching frequencies of up to roughly 70 percent because they confer protection against the parasite. But when these alleles combine, the consequences escalate. People inheriting one Southeast Asian deletion allele and one α-globin deletion develop hemoglobin H disease, in which excess β-globin chains form useless β4 tetramers, and about 10 percent of these patients become transfusion dependent. The most devastating outcome occurs in fetuses that inherit no functional α-globin genes at all, a condition known as hemoglobin Bart’s hydrops fetalis syndrome, or BHFS, which normally causes death in utero during the second or third trimester.

Current options for the most severe patients are limited. Hematopoietic stem cell transplantation is the only curative treatment, but it requires a human leukocyte antigen-matched donor, and even when a donor is available, graft-versus-host disease and transplant-related mortality remain real risks. A small but growing number of BHFS survivors, salvaged by intrauterine transfusions and intensive neonatal care, face lifelong transfusion dependence and iron chelation. This therapeutic gap is what drew the Oxford team to an unusual idea: rather than trying to replace the missing α-globin gene, why not switch back on the embryonic gene that once did its job?

The logic rests on a quirk of human development. The α-globin locus on chromosome 16 contains, in sequence, the enhancers R1 through R4, the embryonic ζ-globin gene HBZ, and the two fetal and adult α-globin genes HBA2 and HBA1. During the first, primitive wave of red blood cell formation, ζ-globin is fully expressed and assembles into functional hemoglobin tetramers, including Hb Portland 1 (ζ2γ2) and Hb Portland 2 (ζ2β2), which can substitute for fetal and adult hemoglobins. But by six to seven weeks of gestation, as definitive hematopoiesis takes over, ζ-globin is completely silenced and remains off for the rest of life. Crucially, the most common disease-causing allele, the Southeast Asian deletion, removes both α-globin genes while leaving the enhancers and the ζ-globin gene intact, meaning that in many patients the dormant embryonic gene is still sitting there, waiting to be unlocked.

To find the off switch, the researchers first built an elegant mouse model called DZIA, in which the 4.4-kilobase segment containing the ζ-globin gene was replaced with a modified α-globin gene carrying twenty silent single-nucleotide polymorphisms that allowed its transcripts to be distinguished from endogenous ones. The result was striking: the substituted gene, placed in exactly the position of the embryonic gene, was fully transcribed in definitive erythroid cells, accounting for 40 to 50 percent of total α-like globin output, roughly equivalent to the combined output of two endogenous α-globin genes. This proved that the silencing machinery is encoded locally within that 4.4-kilobase region, not in distant flanking sequences or in the gene’s position within the chromosome’s three-dimensional architecture.

Next came a CRISPR-Cas9 saturation mutagenesis screen across the ζ-globin promoter. Using a reporter mouse in which ζ-globin expression is marked by a fluorescent protein, and refining the search in an immortalized mouse proerythroblast line, the team tiled 47 guide RNAs across 700 base pairs upstream of the transcription start site. The screen converged on two discrete repressive elements: predicted binding motifs for the transcription factors BCL11A and ZBTB7A, also known as LRF. Disrupting the BCL11A motif alone derepressed ζ-globin to about 4 percent of total α-like globin, the LRF motif alone to about 18 percent, and combined disruption, introduced with a cytosine base editor, pushed expression to roughly 26 percent, marginally more than the sum of the individual effects.

The team then built a mouse model carrying these promoter edits, termed ZPE, and crossed it with a new BHFS model that precisely replicates the human Southeast Asian deletion, including its flanking sequences. Untreated homozygous deletion embryos, which produce no α-globin at all, develop normally until embryonic day 15.5, when the last primitive, ζ-globin-expressing red cells disappear from circulation. Thereafter they become pale and growth restricted, develop edema, and by day 17.5 suffer severe hemolytic anemia with large numbers of immature, nucleated erythroblasts churning out nonfunctional β4 tetramers. Embryos carrying the promoter edits on top of the deletion showed dramatic improvement at day 17.5, with near-normal enucleated red blood cells expressing about 7.5 percent ζ-globin mRNA and producing detectable Hb Portland 2. The embryonic protein was, in effect, standing in for the missing adult one.

The human work followed a parallel path. In the HUDEP-2 definitive erythroid cell line, the researchers found that the architecture of the ζ-globin promoter differs subtly from the mouse: two consensus BCL11A motifs lie 148 base pairs apart, with the proximal one overlapping the essential CCAAT box, so editing that site is ineffective. The distal BCL11A site and the LRF site, however, proved to be the productive targets. Base editing both sites raised ζ-globin to about 15 percent of total α-like globin, comparable to levels achieved by knocking out both repressor genes entirely, while leaving erythroid differentiation untouched. Mechanistically, the authors propose a competition model: LRF binding, just 18 base pairs from the CCAAT box, blocks NF-Y from opening the chromatin, and together with BCL11A it prevents the master activator GATA1 from engaging the promoter. When both repressive motifs are mutated, GATA1 newly binds and the gene fires.

The most clinically resonant experiments used primary human CD34-positive stem cells from healthy donors, patients with hemoglobin H disease and a 21-week BHFS fetus. Adenine and cytosine base editors achieved efficiencies of 25 to 90 percent at the two sites, and edited cells differentiated normally. After normalizing for editing efficiency, the ratio of α-like to β-like globin in the hemoglobin H patient samples rose from 24.8 percent, a dangerously low level, to 48.4 percent, with ζ-globin contributing about half of the α-like output. In the BHFS fetal cells, the ratio climbed from 17.1 percent to 50.5 percent. The authors argue that restoring this ratio to around 0.5 would likely be sufficient to rescue the severe α-thalassemia phenotype, and HPLC analysis of edited BHFS cells showed a corresponding reduction in the pathological β4 tetramers that cause the disease.

Caution remains appropriate. Hb Portland 2 has weaker subunit interactions and higher oxygen affinity than adult hemoglobin, and its physiological behavior in adult life must be characterized before clinical application. Editing efficiencies in primary stem cells vary, off-target effects and long-term engraftment have yet to be rigorously assessed, and the authors note that residual low-level ζ-globin expression seen in human carriers appears to involve human-specific mechanisms absent from the mouse. Still, the study establishes a clear road map: a compact, locally acting cis-regulatory module enforces embryonic gene silencing, and precise base editing can dismantle it. Beyond α-thalassemia, the work reinforces an emerging paradigm, already validated by fetal hemoglobin induction in sickle cell disease and β-thalassemia, that developmentally silenced paralogs can be unlocked to compensate for adult gene defects, offering a potentially generalizable route to autologous genome-editing therapies for severe inherited disorders that today demand lifelong transfusion or a matched donor.

Subject of Research: Reactivation of the embryonic ζ-globin gene by promoter base editing as a therapeutic strategy for severe α-thalassemia

Article Title: Reactivation of the embryonic ζ-globin gene ameliorates severe forms of α-thalassemia

Article References: Liu, S., Ejaz, A., King, A. J., Olijnik, A.-A., Sloane-Stanley, J., Scott, C., Amid, A., Biggs, D., Davies, B., Eglinton, J., Martyn, G., Crossley, M., Babbs, C., Kassouf, M. T., & Higgs, D. R. (2026). Reactivation of the embryonic ζ-globin gene ameliorates severe forms of α-thalassemia. Nature Genetics, 58(10), 2619-2629. https://doi.org/10.1038/s41588-026-02770-0

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02770-0

Keywords: α-thalassemia, ζ-globin, gene editing, base editing, BCL11A, ZBTB7A, hemoglobin, erythropoiesis, hydrops fetalis, CRISPR, globin gene regulation, hemoglobinopathies

Cancer-related anemia, often abbreviated CRA, arises from a tangle of mechanisms: the tumor itself can suppress red blood cell production through inflammatory cytokines, chemotherapy and radiotherapy damage the bone marrow, nutritional iron deficiency can develop, and bleeding or kidney dysfunction can compound the deficit. The result is a reduced hemoglobin concentration, which starves tissues of oxygen and manifests clinically as fatigue, breathlessness, dizziness, and diminished quality of life. In late-stage disease, where patients are often receiving their third or subsequent lines of treatment, the cumulative toxicity of repeated regimens makes the problem especially acute.

The Beijing study quantified the severity of anemia using standard hemoglobin thresholds. Among the 1,006 anemic patients, the average hemoglobin level was 96.85 grams per liter, with a standard deviation of 14.32. Mild anemia accounted for just over half of cases at 51.3 percent, moderate anemia for 35.8 percent, severe anemia for 10.2 percent, and extremely severe anemia for 2.7 percent. In other words, roughly one in eight anemic patients had fallen into a range serious enough to threaten daily functioning and potentially require urgent intervention.

Red blood cell morphology added another layer of diagnostic insight. Normocytic anemia — red cells of normal size — predominated at 75.3 percent of cases, a pattern consistent with the anemia of chronic disease and marrow suppression rather than classic iron deficiency. Macrocytic anemia, in which red cells are abnormally large, followed at 20.7 percent, a finding that can reflect chemotherapy effects on DNA synthesis, folate or vitamin B12 disturbances, or certain targeted therapies. Microcytic anemia, typically associated with absolute iron deficiency, was the least common at just 4.0 percent, suggesting that straightforward iron replacement alone would address only a small fraction of the problem in this population.

The distribution of severity varied meaningfully by tumor type. Advanced lung cancer and gastrointestinal tumors had the highest proportions of mild anemia, at 56.2 percent and 55.4 percent respectively, meaning most of their anemic patients remained in the least severe category. Gynecologic tumors told a different story: 18.2 percent of anemic patients with these cancers had severe anemia, a rate significantly higher than the 6.3 percent seen in advanced lung cancer and the 6.0 percent in breast cancer. The authors suggest this may reflect the biology and treatment of gynecologic malignancies, including the potential for tumor-related and treatment-related blood loss, though the retrospective design cannot pin down the exact mechanisms.

Perhaps the most sobering finding concerns treatment. Despite the availability of established therapies for cancer-related anemia — iron supplementation, erythropoiesis-stimulating agents, and red blood cell transfusion — only 22.4 percent of the 1,006 anemic patients received any anti-anemia therapy. The treatment gap tracked severity closely: just 10.1 percent of patients with mild anemia were treated, compared with 59.2 percent of those with severe anemia and 96.3 percent of those with very severe anemia. The pattern suggests that clinicians often wait until anemia becomes debilitating before intervening, a reactive approach that the study’s authors argue should give way to earlier, standardized management.

To identify who is most at risk of severe anemia, the researchers performed multivariate logistic regression, a statistical technique that isolates the independent effect of each factor while controlling for the others. The results were revealing. A Karnofsky Performance Status score of 60 or higher — a measure of a patient’s functional ability, where higher scores indicate better day-to-day functioning — was associated with an approximately 62 percent reduction in the odds of severe anemia, with an odds ratio of 0.38. This suggests that a patient’s overall physical condition, and the biological reserve it represents, plays a protective role against the steepest hemoglobin declines.

Tumor type emerged as another independent determinant. Compared with lung cancer, gynecologic tumors carried roughly 3.3 times the risk of severe anemia, with an odds ratio of 3.33, while gastrointestinal tumors carried 1.83 times the risk. A prior history of blood transfusion was also linked to a 76 percent increase in the risk of severe anemia, with an odds ratio of 1.76 — a finding that likely marks patients whose anemia has already proven refractory or recurrent, rather than transfusion itself causing the problem. Notably, age, gender, history of prior tumors, the specific third-line regimen, stage IV disease at initial diagnosis, liver metastasis, and lung metastasis showed no independent association with severe anemia, indicating that these commonly monitored variables are less predictive than performance status and tumor origin.

The study joins a lineage of large surveys, including the European Cancer Anaemia Survey, that have documented the high prevalence and undertreatment of anemia in oncology. What distinguishes the new work is its focus on a heavily pretreated population — patients on third-line or later therapy — a group that is often underrepresented in clinical trials yet increasingly common as cancer survival extends and treatment sequences lengthen. With an incidence of 65.1 percent in this setting, anemia is not a marginal side effect but a central feature of advanced disease management, with direct consequences for treatment tolerance, dosing intensity, and quality of life.

The authors conclude that greater attention and standardized management of anemia should be implemented among cancer patients, and the data point to concrete priorities: routine hemoglobin monitoring and earlier intervention for patients with gynecologic and gastrointestinal tumors, proactive anemia assessment for those with poor performance status, and a lower threshold for treatment before hemoglobin levels fall into the severe range. As cancer care continues to extend lives through successive lines of therapy, the study serves as a reminder that the blood counts of these patients deserve the same systematic attention as their tumors.

Subject of Research: Cancer-related anemia in advanced cancer patients receiving third-line or higher anti-cancer treatment

Article Title: A survey of the current status of cancer-related anemia in 1006 advanced cancer patients undergoing third-line or higher anti-cancer treatment: a multicenter retrospective study in nine tertiary hospitals in Beijing area

Article References: Xu, J., Zhang, Q., Kang, N., Yan, D., Feng, Y., Yin, Y., Liu, J., Jiang, J., Yuan, J., Liu, Z., Han, X., Li, X., & Hou, L. (2026). A survey of the current status of cancer-related anemia in 1006 advanced cancer patients undergoing third-line or higher anti-cancer treatment: a multicenter retrospective study in nine tertiary hospitals in Beijing area. BMC Cancer. https://doi.org/10.1186/s12885-026-17100-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17100-0

Keywords: cancer-related anemia, advanced cancer, hemoglobin, chemotherapy, gynecologic tumors, gastrointestinal tumors, lung cancer, performance status, blood transfusion, retrospective study, anemia treatment, oncology